Results 141 to 150 of about 37,793 (319)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Autism and mild epilepsy associated with a de novo missense pathogenic variant in the GTPase effector domain of DNM1

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView., 2023
Abstract Dynamin 1 is a GTPase protein involved in synaptic vesicle fission, which facilitates the exocytosis of neurotransmitters necessary for normal signaling. Pathogenic variants in the DNM1 gene are associated with intractable epilepsy, often manifested as infantile spasms at onset, developmental delay, and a movement disorder, and are located in ...
Davide Mei   +4 more
wiley   +1 more source

Single‐Cell Dissection Reveals Immune Dysregulation After CD5 or CD7‐Directed Chimeric Antigen Receptor T‐Cell Therapy

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA/TCR/BCR sequencing reveals that 5CAR therapy in T‐ALL induces T‐cell exhaustion, reduces EBV‐associated TCRs, lowers TCR/BCR diversity, and increases NK/DC/monocyte activation and function. In contrast, 7CAR therapy reduces multiple pathogen‐associated TCRs, enhances NK cell activation and function, decreases monocyte activation, and ...
Yuechen Luo   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy